Drug trial aims to shrink dangerous kidney tumors
NCT ID NCT05252585
Summary
This study is checking the safety and effectiveness of the drug everolimus for Taiwanese adults with tuberous sclerosis complex who have non-cancerous kidney tumors called angiomyolipomas. It will follow a small group of eligible patients for about a year to see if the drug shrinks the tumors and monitor for side effects. The goal is to better control these growths to prevent complications like bleeding.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL ANGIOMYOLIPOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novartis Investigative Site
Taichung, Taiwan ROC, 40201, Taiwan
-
Novartis Investigative Site
Taoyuan District, Taiwan ROC, 33305, Taiwan
-
Novartis Investigative Site
Taipei, 10002, Taiwan
-
Novartis Investigative Site
Taoyuan District, 33305, Taiwan
Conditions
Explore the condition pages connected to this study.